Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1871-8. doi: 10.1158/1055-9965.EPI-10-0216.
Sex steroid hormone receptors mediate essential processes in normal prostate growth and contribute to prostate cancer development.
In this study, we investigated the association between common inherited variation of the AR, ESR1, and ESR2 genes and two clinically relevant traits: the risk of developing aggressive prostate cancer and the response to androgen deprivation therapy (ADT) in a hospital-based cohort. A total of 43 tagging single nucleotide polymorphisms covering the loci of AR (n = 4), ESR1 (n = 32), and ESR2 (n = 7) were successfully genotyped in 4,073 prostate cancer cases.
None of these single nucleotide polymorphisms were significantly associated with disease aggressiveness as assessed by the D'Amico risk classification, pathologic stage, or the response to ADT.
Our results suggest that common genetic variations in AR, ESR1, or ESR2 are not strongly associated with prostate cancer aggressiveness or response to ADT.
Our study did not find convincing evidence of inherited variations in the major receptors for androgens and estrogens and their associations with prostate cancer traits.
性激素受体介导正常前列腺生长的重要过程，并有助于前列腺癌的发展。
在这项研究中，我们调查了 AR、ESR1 和 ESR2 基因常见遗传变异与两种临床相关特征之间的关联：在基于医院的队列中，发展侵袭性前列腺癌的风险和对雄激素剥夺治疗（ADT）的反应。总共在 43 个 AR（n = 4）、ESR1（n = 32）和 ESR2（n = 7）基因座的标记单核苷酸多态性中成功地对 4073 例前列腺癌病例进行了基因分型。
这些单核苷酸多态性均与 D'Amico 风险分类、病理分期或 ADT 反应评估的疾病侵袭性无关。
我们的结果表明，AR、ESR1 或 ESR2 中的常见遗传变异与前列腺癌侵袭性或对 ADT 的反应没有很强的相关性。
我们的研究没有发现雄激素和雌激素主要受体的遗传变异及其与前列腺癌特征之间存在关联的令人信服的证据。
